 |
|
 |
 |
 |
|
|
DIADEXUS APPOINTS NEW RESEARCH AND DEVELOPMENT EXECUTIVES Ronald M. Lindsay, Ph.D. to be Vice President and Chief Scientific Officer, Robert L. Wolfert, Ph.D., Named Vice President of Diagnostics Santa Clara, CA - November 30, 2000 - diaDexus today announced the appointment of Ron Lindsay, Ph.D., as vice president of research and development and chief scientific officer and Bob Wolfert, Ph.D., as vice president of diagnostics. Dr. Lindsay joins diaDexus from Millennium Pharmaceuticals, where he was senior vice president, Biotherapeutics. Previously, Dr. Lindsay served as vice president, research and development of Millennium BioTherapeutics where he was responsible for programs in genomic discovery, protein sciences and functional genomics. Dr. Lindsay also helped manage the collaboration between Millennium BioTherapeutics and Eli Lilly Pharmaceuticals. Before joining Millennium, Dr. Lindsay spent nine years with Regeneron Pharmaceuticals, Tarrytown, NY, where he was a founding scientist. As vice president, Neurobiology, Dr. Lindsay was responsible for studies that advanced three proteins from molecular discovery into clinical trials. Prior to Regeneron, Dr. Lindsay spent four years at the Sandoz Institute for Medical Research as head of cell biology and seven years with the Medical Research Council, both in London England. Dr. Lindsay received his B.S. in chemistry from the University of Glasgow, his Ph.D. in biochemistry from the University of Calgary in Alberta, and conducted his postdoctoral studies at the Friedrich Miescher Institute in Basel, Switzerland. Dr. Lindsay is author of numerous patents and over 150 major scientific articles. Dr. Wolfert joins diaDexus from Atairgin Technologies where he served as vice president of research and development, directing programs for the detection and treatment of ovarian and breast cancers. Previously, Dr. Wolfert was director of research at Hybritech/Beckman Coulter, where he was responsible for diagnostic research efforts in prostate and breast cancers, osteoporosis and neurological and cardiovascular disease. Dr. Wolfert received his B.A. degree in chemistry and biology from Cornell University, and earned his doctorate in biochemistry and molecular immunology from Tufts University School of Medicine. He completed his training as a Research Fellow of the Leukemia Society in immunopathology at the Scripps Institute for Biomedical Research, in La Jolla California. He is author or co-author of several patents and over 50 scientific publications. diaDexus is a post-genomics company focused on translating raw genomics data into novel diagnostic and therapeutic products. diaDexus has utilized genomics and bioinformatics to identify thousands of disease-associated molecular targets. Currently diaDexus has two diagnostic product candidates in late-stage preclinical development. diaDexus is located in Santa Clara, California. For more information, please visit the diaDexus web site at www.diadexus.com. |
|
|
|
